Ahmad E,Lim S,Lamptey R,Webb DR,Davies MJ DR .2022 .Type 2 diabetes. , 400(10365) : 1803-1820.
Artasensi A,Pedretti A,Vistoli G,Fumagalli L G .1987 .Type 2 Diabetes mellitus: A review of multitarget drugs. Molecules, 25(8) : .
Aryan Z,Ghajar A,Faghihi-Kashani S,Afarideh M,Nakhjavani M,Esteghamati A .2018 .Baseline high-sensitivity c-reactive protein predicts macrovascular and microvascular complications of Type 2 diabetes: A population-based study. Ann. Nutr, 72(4) : 287-295.
Atkinson MA,Campbell-Thompson M,Kusmartseva I,Kaestner KH .2020 .Organisation of the human pancreas in health and in diabetes. Diabetologia., 63(10) : 1966-1973.
Bahreynian M,Qorbani M,Motlagh ME,Heshmat R,Khademian M,Kelishadi R M .2018 .Association of serum 25-hydroxyvitamin D levels and liver enzymes in a nationally representative sample of iranian adolescents: The childhood and adolescence surveillance and prevention of adult noncommunicable disease study. Int. J. Prev. Med, 9(24) : 24.
Bellary S,Kyrou I,Brown JE,Bailey CJ .2021 .Type 2 diabetes mellitus in older adults: Clinical considerations and management. Nat. Rev. Endocrinol., 17(9) : 534-548.
Caussy C,Aubin A,Loomba R .2021 .The relationship between type 2 diabetes, NAFLD, and cardiovascular risk. Curr. Diab. Rep, 21(5) : 15.
Chan CB,Harper ME .2006 .Uncoupling proteins: role in insulin resistance and insulin insufficiency. Curr. Diabetes. Rev., 2(3) : 271-283.
Cheng C,Deng X,Xu K X .2018 .Increased expression of sterol regulatory element binding protein-2 alleviates autophagic dysfunction in NAFLD. Int. J. Mol. Med, 41(4) : 1877-1886.
Chong PL,Laight D,Aspinall RJ,Higginson A,Cummings MH .2021 .A randomised placebo controlled trial of VSL#3(®) probiotic on biomarkers of cardiovascular risk and liver injury in nonalcoholic fatty liver disease. BMC Gastroenterol, 21(1) : 144.
JB. Florez Cole,JC Cole .2020 .Genetics of diabetes mellitus and diabetes complications. Nat. Rev. Nephrol., 16(7) : 377-390.
Dai W,Ye L,Liu A,Wen SW,Deng J,Wu X,Lai Z X .2017 .Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A metaanalysis. Medicine (Baltimore), 96(39) : e8179.
Ferguson D,Finck BN D .2021 .Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat. Rev. Endocrinol., 17(8) : 484-495.
Francisco V,Pino J,González-Gay M,Lago F,Karppinen J,Tervonen O,Mobasheri A,Gualillo O .2022 .A new immunometabolic perspective of intervertebral disc degeneration. Nat. Rev. Rheumatol., 18(1) : 47-60.
Fu R,Li J,Yu H,Zhang Y,Martin Z,C Z .2021 .The Yin and Yang of traditional Chinese and Western medicine. Med. Res. Rev., 41(6) : 3182-3200.
Garg K,Brackett S,Hirsch IB,Garg SK .2020 .NAFLD/NASH and Diabetes. Diabetes Technol. Ther., 22(S1) : S174-s186.
Golabi P,Stepanova M,Pham HT,Cable R,Rafiq N,Bush H,Gogoll T,Younossi ZM .2018 .Nonalcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). BMJ Open Gastroenterol. , 5(1) : e000198.
Guo D,Xiao L,Hu H,Liu M,Yang L,Lin X .2018 .FGF21 protects human umbilical vein endothelial cells against high glucose-induced apoptosis via PI3K/Akt/Fox3a signaling pathway. J. Diabetes Complicat., 32(8) : 729-736.
Javed Z,Papageorgiou M,Deshmukh H,Kilpatrick ES,Mann V,Corless L,Abouda G,Rigby AS,Atkin SL,Sathyapalan T .2019 .A randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients, 11(1) : 188.
Lin Z,Yang F,Sun L,Gao J,Cao Y,Qiu H,Zhan X H .2018 .Systematically analyses of the common dysregulated networks to understand the common pathologies between T2D and atherosclerosis. Gene, 671(5) : 110-116.
Liu FS,Li Y,Guo XS,Liu RC,Zhang HY,Li Z HY .2022 .Advances in traditional Chinese medicine as adjuvant therapy for diabetic foot. World J. Diabetes, 13(10) : 851-860.
Liu XJ,Hu XK,Yang H,Gui LM,Cai ZX,Qi MS,Dai CM .2022 .A review of traditional Chinese medicine on treatment of diabetic nephropathy and the involved mechanisms. Am. J. Chin. Med, 50(7) : 1739-1779.
Liu Y,Zhang Y,Zhang K,Wang Y .2018 .Protocatechuic acid reduces H2O2-induced migration and oxidative stress of fibroblast-like synoviocytes in rheumatoid arthritis by activating Nrf2-Keap1 signaling pathway. World J. Tradit. Chin. Med, 4(1) : 28-35.
Nauck MA,Wefers J,Meier JJ .2021 .Treatment of type 2 diabetes: Challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol., 9(8) : 525-544.
Peng H,Wang S,Wang M,Ye Y,Xue E,Chen X,Wang X,Fan M,Gao W,Qin X,Wu Y,Chen D,Li J,Hu Y,Wang L,Wu T .2022 .Nonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study. Metabolism, 133 : 155220.
Powell EE,Wong VW,Rinella M .2021 .Nonalcoholic fatty liver disease. Lancet, 397(10290) : 2212-2224.
Stefan N and Cusi K .2022 .A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol., 10(4) : 284-296.
Targher G,Byrne CD,Tilg H CD .2020 .NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications. , 69(9) : 1691-1705.
Targher G,Corey KE,Byrne CD,Roden M .2021 .The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat. Rev. Gastroenterol. Hepatol., 18(9) : 599-612.
Tilg H,Adolph TE,Dudek M,Knolle P .2021 .Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity. Nat. Metab, 3(12) : 1596-1607.
Tinajero MG,Malik VS .2021 .An update on the epidemiology of type 2 diabetes: A global perspective. Endocrinol. Metab. Clin. North Am., 50(3) : 337-355.
Viigimaa M,Sachinidis A,Toumpourleka M,Koutsampasopoulos K,Alliksoo S,Titma T .2020 .Macrovascular complications of type 2 diabetes mellitus. Curr. Vasc. Pharmacol., 18(2) : 110-116.
Vural H,Armutcu F,Akyol O,Weiskirchen R O .2021 .The potential pathophysiological role of altered lipid metabolism and electronegative lowdensity lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. Clin. Chim. Acta., 523(5) : 374-379.
Wang N,Wang Y,Zhang W,Chen Y,Chen X,Wang C,Li Q,Chen C,Jiang B,Lu Y .2020 .C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes. Diabetes Metab Res Rev., 36(2) : e3210.
Wu D,Wu C,Zhong Y C .2018 .The association between paraoxonase 1 activity and the susceptibilities of diabetes mellitus, diabetic macroangiopathy and diabetic microangiopathy. J. Cell. Mol. Med, 22(9) : 4283-4291.
Wu WKK,Zhang L,Chan MTV .2018 .Autophagy, NAFLD and NAFLD-related HCC. Adv. Exp. Med, 1061(2) : 127-138.
Yun JS,Ko SH .2021 .Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. , 123(11) : 154838.